TY - JOUR
T1 - Cost-utility analysis of a national project to reduce hypertension in Israel
AU - Yosefy, Chaim
AU - Ginsberg, Gary
AU - Viskoper, Reuven
AU - Dicker, Dror
AU - Gavish, Dov
PY - 2007/11/28
Y1 - 2007/11/28
N2 - Background: This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program. Methods: Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs. Results: Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality. Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million. Conclusion: The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.
AB - Background: This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program. Methods: Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs. Results: Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality. Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million. Conclusion: The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.
UR - http://www.scopus.com/inward/record.url?scp=38849199735&partnerID=8YFLogxK
U2 - 10.1186/1478-7547-5-16
DO - 10.1186/1478-7547-5-16
M3 - Article
AN - SCOPUS:38849199735
SN - 1478-7547
VL - 5
JO - Cost Effectiveness and Resource Allocation
JF - Cost Effectiveness and Resource Allocation
M1 - 16
ER -